Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis
International Journal of Clinical Oncology · 2025-03 · 30 (3) · 489-496
DOI: 10.1007/s10147-025-02702-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 06.02.2025. Verfasst von Hirotaka Shinomiya und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho Chuo-Ku, Kobe, Hyogo, 650-0017, J…. Hauptthemen laut MEDLINE: Cisplatin, Maxillary Sinus Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Labor Sciences Research Grant for Clinical Cancer Research, the National Cancer Center Research and Development Fund, U.S. Army Medical Department Center and School, Health Readiness Center of Excellence.
Abstract (Originalsprache)
Background
JCOG1212 is a dose-finding and efficacy confirmatory study of concurrent superselective intra-arterial infusion of cisplatin and radiotherapy (RADPLAT) for locally advanced primary squamous cell carcinoma of the maxillary sinus (cT4a,bN0M0). In this study, we report the results of the final analysis of the efficacy confirmation phase for the T4a cohort with 5-year follow-up data to evaluate the late adverse events and long-term efficacy.
Methods
Based on the results of the dose-finding phase, the efficacy confirmation phase consisted of seven weekly intra-arterial infusions of cisplatin 100 mg/m 2 combined with radiotherapy (70 Gy). The 5-year prognosis and late adverse events were evaluated.
Results
Between April 2014 and August 2018, 64 patients were included in the analysis (one ineligible patient was excluded); 31 patients were treated with three-dimensional conformal radiation therapy (3D-CRT) and 33 with intensity modulated radiation therapy (IMRT). The 5-year overall survival, event-free survival, and local event-free survival was 71.9, 54.7, and 57.5%, respectively. In terms of late adverse events, grade 3 or higher non-hematologic toxicity was observed in 42.9% of 63 patients (retinopathy: 12, cataract: 10, osteonecrosis of mandible: 4, etc.). Grade 3 and 4 cataracts of affected side appeared in 22.6% (7/31) of the 3D-CRT group compared to 3.1% (1/32) in the IMRT group. Twenty-one patients had died, with 15 from the primary disease, 5 from other causes, and 1 from treatment-related cause.
Conclusion
The prognosis of RADPLAT was favorable after 5-year follow-up with acceptable late adverse events and low proportion of treatment related death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho Chuo-Ku, Kobe, Hyogo, 650-0017, Japan. hshino@med.kobe-u.ac.jp.
- Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Radiation Oncology, Tonan Hospital, Sapporo, Japan.
- Department of Otolaryngology, Head and Neck Surgery, Tohoku University Hospital, Sendai, Japan.
- Department of Otolaryngology, Head and Neck Surgery, University of Tokyo Hospital, Tokyo, Japan.
- Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Förderung
- Health and Labor Sciences Research Grant for Clinical Cancer Research
- the National Cancer Center Research and Development Fund
- U.S. Army Medical Department Center and School, Health Readiness Center of Excellence
- Kobe University
Zitieren
APA
Shinomiya, H., Matsuura, K., Onimaru, R., Ohkoshi, A., Saito, Y., Tachibana, H., Shiga, K., Ueda, T., Asada, Y., Uemura, H., Beppu, T., Seto, A., Yasumatsu, R., Nakahira, M., Omura, G., Asakage, T., Minami, S., Fujii, T., Hirayama, Y., …, & Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG) (2025). Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis. International Journal of Clinical Oncology, 30(3), 489-496. https://doi.org/10.1007/s10147-025-02702-8
Vancouver
Shinomiya H, Matsuura K, Onimaru R, Ohkoshi A, Saito Y, Tachibana H, et al. Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis. International Journal of Clinical Oncology. 2025;30(3):489-496. doi:10.1007/s10147-025-02702-8
BibTeX
@article{Shinomiya2025,
author = {Shinomiya, Hirotaka and Matsuura, Kazuto and Onimaru, Rikiya and Ohkoshi, Akira and Saito, Yuki and Tachibana, Hiroyuki and Shiga, Kiyoto and Ueda, Tsutomu and Asada, Yukinori and Uemura, Hirokazu and Beppu, Takeshi and Seto, Akira and Yasumatsu, Ryuji and Nakahira, Mitsuhiko and Omura, Go and Asakage, Takahiro and Minami, Shujiro and Fujii, Takashi and Hirayama, Yuji and Yoshida, Daisuke and Nakamura, Kenichi and Sasaki, Keita and Mizusawa, Junki and Fukuda, Haruhiko and Homma, Akihiro and Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG), Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG)},
title = {Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis},
journal = {International Journal of Clinical Oncology},
year = {2025},
volume = {30},
number = {3},
pages = {489--496},
doi = {10.1007/s10147-025-02702-8}
}
EUVIMED